Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.00: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality.
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling Amtagvi (lifileucel), the first approved TIL cell therapy for advanced melanoma, and Proleukin (aldesleukin). Revenue from Amtagvi infusions is recognized upon infusion; Proleukin sells through... Read more
Sell if holding. Engine safety override at $4.00: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Score 5.9/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Iovance Biotherapeutics, Inc.
Latest news
- NEWS Iovance Biotherapeutics Says Therapeutic Goods Administration Of Australia Grants Approval With Conditions Of Amtagvi, T — benzinga Jun 3, 2026 positive
- NEWS Iovance Biotherapeutics Announces Allowance To Proceed From FDA For Investigational New Drug Application For Phase 1/2 B — benzinga Jun 1, 2026 positive
- NEWS Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $14 — benzinga May 7, 2026 positive
- NEWS Iovance Biotherapeutics Sees FY2026 Sales $350.000M-$370.000M vs $370.477M Est — benzinga May 7, 2026 neutral
- NEWS Iovance Biotherapeutics Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $71.430M Miss $78.396M Estimate — benzinga May 7, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Volatile — 9.0% daily ATR makes tight stops impractical. Position-size conservatively.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.00: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.9/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 61, MACD bullish. Prior stop was $3.72. Score 5.9/10, moderate confidence.
Take-profit target: $7.66 (+91.5% upside). Prior stop was $3.72. Stop-loss: $3.72.
Quality below floor (3.2 < 4.0).
Iovance Biotherapeutics, Inc. trades at a P/E of N/A (forward -13.3). TrendMatrix value score: 7.7/10. Verdict: Sell.
16 analysts cover IOVA with a consensus score of 4.0/5. Average price target: $9.
What does Iovance Biotherapeutics, Inc. do?Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling Amtagvi (lifileucel), the first...
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company selling Amtagvi (lifileucel), the first approved TIL cell therapy for advanced melanoma, and Proleukin (aldesleukin). Revenue from Amtagvi infusions is recognized upon infusion; Proleukin sells through distributors for use in Amtagvi regimens and other oncology applications.